{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"7770","value":"17000"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"}],"units":"Participants"}],"description":"AUCinf of capmatinib was estimated by non-compartmental analysis. AUCinf is the area under the plasma concentration-time curve extrapolated to infinity. Plasma concentrations of capmatinib were measured using validated LCMS/MS methods with a LLOQ of approximately 1.0 ng/mL.\n\nOnly a subset of participants from Cohorts 1a, 1b, 2, 3, 4, 5a and 5b, who had an extensive PK collection schedule, were included in this analysis","dispersionType":"Standard Deviation","groups":[{"description":"Participants from Cohorts 1a, 1b, 2, 3, 4, 5a and 5b who received capmatinib in fasted state","id":"OG000","title":"Cohorts 1-5: Capmatinib Administration in Fasted State"}],"paramType":"MEAN","populationDescription":"Participants from Cohorts 1a, 1b, 2, 3, 4, 5a and 5b who received at least one dose of capmatinib with extensive PK sampling collection and an evaluable PK parameter (AUCinf for capmatinib) at the specified time points. Participants received capmatinib under the same administration conditions (fasted state) and were pooled together for analysis","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 at pre-dose, 0.5, 1, 2, 4, 6 and 8 hours post-dose. Each Cycle is 21 days","title":"Area Under the Plasma Concentration-time Curve From Zero to Time Infinity (AUCinf) of Capmatinib","type":"SECONDARY","unitOfMeasure":"nanogram * hour / mililiter (ng*h/ml)"}